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Dysfunction in the dopaminergic and serotonergic neurotransmitter systems has been
demonstrated to be important in the etiology of borderline personality disorder (BPD).We
investigated the relationship of two BPD risk factors, the HTR1A promoter polymorphism
-1019C>G (rs6295) and the dopamine transporter (DAT1) repeat allele, with BPD in amajor
depressive disorder cohort of 367 patients. Out-patients with major depressive disorder
were recruited for two treatment trials and assessed for personality disorders, including
BPD. DNA samples were collected and the rs6295 polymorphism was detected with a
TaqMan® assay. The DAT1 repeat allele was genotyped using a modiﬁed PCR method.
The impact of polymorphisms on BPD was statistically analyzed using uncontrolled logistic
and multiple logistic regression models. BPD patients had higher frequencies of the DAT1
9,9 (OR = 2.67) and 9,10 (OR = 3.67) genotypes and also those homozygous HTR1A G
allele (OR = 2.03). No signiﬁcant interactions between HTR1A and DAT1 genotypes, were
observed; however, an increased risk of BPD was observed for those patients who were
either 9,10; G,G (OR = 6.64) and 9,9; C,G (OR = 5.42). Furthermore, the odds of BPD in
patients exhibiting high-risk variants of these two genes differed from those of patients
in low-risk groups by up to a factor of 9. Our study provides evidence implicating the
importance of the serotonergic and dopaminergic systems in BPD and that the interaction
between genes from different neurotransmitters may play a role in the susceptibility to
BPD.
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INTRODUCTION
Borderline personality disorder (BPD) is a psychiatric diagnosis in
the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV)manual that describes a prolonged disturbance
of personality function characterized by depth and variability of
moods. These disturbances can have a pervasive negative impact
on many or all of the psychosocial facets of life. Attempted suicide
and completed suicide are possible outcomes, especially without
proper care and effective therapy (Black et al., 2004). Onset of
symptoms typically occurs during adolescence or young adult-
hood. In the USA, BPD is estimated to affect 2% of the population
[National Institute of Mental Health, (NIMH)]. Impulsivity and
impulsive-aggression are core characteristics of patients with BPD.
These are heritable traits of temperament associated with suici-
dal and aggressive behaviors in patients with BPD (Oquendo and
Mann, 2000; Soloff et al., 2000a).
The etiology of BPD is still not clear. However, twin studies have
found that if one identical twin met the criteria for BPD, the other
also met the criteria in 35–69% of cases (Loranger et al., 1982;
Torgersen, 2000; Zanarini et al., 2004; Distel et al., 2008b). Several
studies have suggested that traits related to BPD are inﬂuenced by
genes (Torgersen, 2000; Torgersen et al., 2000; Joyce et al., 2006,
2009; Distel et al., 2008a) including genes relating to serotonergic
and dopaminergic neurotransmission. The dopaminergic system
is involved in cognitive and emotional processing and the reg-
ulation of impulsive behaviors: dysfunction of these processes
have been related to BPD symptoms (Friedel, 2004), which may
stem from multiple factors, including a genetic component. Sev-
eral studies have illustrated the role of dopaminergic genes in the
etiology of BPD and associated traits, including the dopamine
transporter (DAT1; Joyce et al., 2006, 2009; Giegling et al., 2008).
Indeed, in a previous study, we demonstrated that the DAT1
9-repeat allele to be a signiﬁcant genetic risk factor for BPD (Joyce
et al., 2006). Furthermore, animal research suggests that repeated
exposure to social stress has long-term effects on DAT1 density
(Lucas et al., 2004) and that DAT1 knock-out mice demonstrate
abnormalities of social interaction (Rodriguiz et al., 2004). These
studies highlight the importance of the dopaminergic system, in
particular DAT1, in the neurobiology of BPD.
Many studies have also reported serotonergic dysfunction
in BPD including genetic, behavioral, and neuroimaging stud-
ies investigating neurobiological correlates in BPD individuals
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(Hollander et al., 1994; Soloff et al., 2000b, 2007; Leyton et al.,
2001; Bennett et al., 2002; Paris et al., 2004; Retz et al., 2004;
Gabbard, 2005; Ni et al., 2006a,b, 2009; Pascual et al., 2007;
Zetzsche et al., 2008). Moreover, the effectiveness of SSRIs, such
as ﬂuoxetine, in the treatment of depression in patients with
BPD lends support to the role that serotonin dysfunction plays in
BPD (Goodman et al., 2004). Serotonergic autoreceptors, includ-
ing the serotonin 1A receptor (HTR1A) have been linked to
BPD (Hansenne et al., 2002; Ni et al., 2006a; Soloff et al., 2007;
Zetzsche et al., 2008). Reduced HTR1A activity has been linked
to BPD and suicidal behavior (Hansenne et al., 2002). Further-
more, a polymorphism in the HTR1A promoter region (rs6295)
has been investigated in BPD through genetic and neuroimag-
ing studies (Serretti et al., 2007; Zetzsche et al., 2008; Ni et al.,
2009). Although two of these reports failed to ﬁnd a clear link
between the rs6295 polymorphism and BPD (Serretti et al., 2007;
Ni et al., 2009), Zetzsche et al. (2008) found that in BPD patients
with the G allele, there were signiﬁcant structural changes in
the limbic system when compared to individuals with a C,C
genotype.
Although both serotonergic and dopaminergic pathways have
been implicated in BPD, no previous genetic studies have exam-
ined the joint (interactive) effects of both the DAT1 and HTR1A
variants simultaneously on BPD. Due to the relationships of
these neurotransmitter pathways with BPD etiology, we sought
to determine if there was an interaction between the BPD risk fac-
tor polymorphisms, DAT1 repeat allele and HTR1A 1019C > G
(rs6295), to see if there was an increase in the risk of BPD. Genetic
analyses were performed using a cohort of 367 major depressive




Patients with a principal diagnosis of major depressive disorder
were recruited for twodepression treatment studies aged≥18 years
fromawide variety of sources, includingmental health out-patient
clinics, general practitioners, self-referral, and psychiatric emer-
gency services. No advertising for patients was involved. Exclusion
criteria were minimized, but included a history of schizophre-
nia or mania, a principal current diagnosis of severe alcohol
or drug dependence, or severe current medical illness. In addi-
tion, patients needed to be free of psychotropic medication for a
minimum of 2 weeks, or ﬁve drug half-lives, except for an occa-
sional hypnotic for sleep. Patients also could not have received
in the past 12 months an adequate treatment trial of one of the
trial treatments to which they could be randomized. All patients
were from New Zealand of European descent. In the ﬁrst depres-
sion treatment trial, 194 patients were randomized to ﬂuoxetine
or nortriptyline (Joyce et al., 2002); and in the second trial 173
patients were randomized to interpersonal psychotherapy or cog-
nitive behavior therapy (Luty et al., 2007), giving a total of 367
patients for the current study.
The two trials ran sequentially, in the same university-based
out-patient Clinical Research Unit, and were the only depres-
sion treatment studies being undertaken in the Department
at the time. Both treatment studies had been approved by
the Canterbury (New Zealand) Ethics Committee. After being
referred, patients were screened over the telephone by a research
nurse who conﬁrmed depressive symptoms and checked inclu-
sion and exclusion criteria. Those who appeared suitable for
inclusion were seen by a psychiatrist, senior psychiatric regis-
trar, or clinical psychologist for an initial assessment. After giving
consent, the patient then attended for a detailed clinical assess-
ment. Assessment included the Structured Clinical Interview for
DSM (SCID; Spitzer et al., 1992), which had been expanded to
include assessment of allDSM-III-R andDSM-IVmelancholic and
atypical depression symptoms. Approximately 6 weeks after com-
mencing treatment a trained psychiatrist or clinical psychologist
completed the Structured Clinical Interview for Axis II Person-
ality Disorders (SCID-II; Spitzer, 1987). Other clinician ratings
were the Montgomery-Asberg Depression Rating Scale (MADRS;
Montgomery and Asberg, 1979), the Hamilton Rating Scale for
Depression (HRSD; Hamilton, 1960), and the Mental State Exam-
ination (MSE; Parker et al., 1994). An independent research nurse
completed the MADRS, the HRSD, and the MSE. During the
baseline assessment patients completed a series of self-report
questionnaires, which included the Hopkins Symptom Checklist
(SCL-90; Derogatis et al., 1973), the Structured Clinical Interview
for Personality Disorders Questionnaire (SCID-PQ; First et al.,
1997), the Parental Bonding Instrument (PBI; Parker, 1979) and
the Temperament and Character Inventory (TCI; Svrakic et al.,
1993). After this assessment patients were randomized to ﬂuoxe-
tine or nortriptyline in the ﬁrst treatment trial (Joyce et al., 2002);
and interpersonal psychotherapy or cognitive behavior therapy for
the second treatment trial (Luty et al., 2007). However, in the cur-
rent study, the two sample cohorts were considered to comprise a
single sample, with no distinction made between the two cohorts,
as the treatment variable in each cohort was not of direct inter-
est and did not affect the relationship between allele status and
the criterion variable of interest, BPD diagnosis. DNA was also
collected for genetic studies.
GENOTYPING
Genomic DNA was obtained from peripheral blood using sodium
chloride extraction (Ciulla et al., 1988) and re-suspended in Tris–
EDTA buffer (pH 8.0) and stored at -20◦C until analysis. For
all genotyping positive and negative controls were included. For
DAT1 repeat allele genotyping, data from a previous study was
obtained (Joyce et al., 2006), but for validation purposes 25% of
the sample were re-genotyped using a previously described poly-
merase chain reaction (PCR) method (Sullivan et al., 1997). The
single-nucleotide polymorphism (SNP), located in the promoter
region of the HTR1A gene rs6295 (1019C > G), was genotyped
using a TaqMan® probe (Applied Biosystems, Scoresby, Vic, Aus-
tralia). One allelic probe was labeled with FAM dye, and the other
with ﬂuorescent VIC dye. PCRs were performed in a 384-well
plate format within a total volume of 5 μl containing 2.73 μl of
2× ABgene Universal PCR Master Mix (Advanced Biotechnolo-
gies Ltd, Surrey, UK), 0.07 μl of 40× TaqMan® probe (Applied
Biosystems) and 20 ng of genomic DNA. Plates were placed in
the LightCycler® 480 real-time PCR System (Roche Diagnostics,
Auckland, New Zealand), and heated at 95◦C for 10 min, followed
by 40 cycles of 95◦C for 15 s, 60◦C for 1 min and 72◦C for
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1 s. The ﬂuorescence intensity in each well was measured and
analyzed using the LightCycler® (Roche Diagnostics). Genotypes
were assigned using the end-point genotyping analysis software.
The genotypes of 15% of the samples were veriﬁed by sequencing
(Genetics Analysis Services, University of Otago). The web-based
analysis program SHEsis1 (Shi and He, 2005) was used to check
for deviations in Hardy–Weinberg equilibrium (HWE).
STATISTICAL ANALYSIS
All data was entered into a relational database and subsequently
transferred to the statistical package IBM SPSS (version 20.0) for
statistical analysis. The sample was summarized descriptively to
consider the incidence of BPD in various sub-groups of patients.
Logistic regression analyseswere conducted to investigate the asso-
ciation between BPD and the presence of the G allele of the rs6295
-1019C > G polymorphism; the presence of the DAT1 9-repeat
allele; and the demographic factors of age and gender. Initially a
series of uncontrolled analyses were conducted. Patients were clas-
siﬁed according to theirHTR1A genotype, with those homozygous
for the C allele (subsequently referred to as the C,C variant) con-
sidered to be the reference category and those homozygous for the
G allele (subsequently referred to as the G,G variant) and those
heterozygous with the C and G alleles (subsequently referred to
as the C,G variant) tested against the reference category. Patients
were also classiﬁed according to the status of the 9-repeat allele of
the DAT1 gene, with the 10-repeat polymorphism on both alleles
(subsequently referred to as the 10,10 variant) considered to be
the reference category and the 9-repeat polymorphism on both
alleles (subsequently referred to as the 9,9 variant), and the 9-
repeat and 10-repeat polymorphisms on each allele (subsequently
referred to as the 9,10 variant) being tested against the reference
category. Four patients were found to exhibit the 11-repeat or 12-
repeat polymorphism: these were deleted from the data set before
further analysis.
Any factor appearing to be important from the uncontrolled
analyses was considered for inclusion in a subsequent multiple
logistic regression model. As the analysis was primarily concerned
with associations between BPD and the DAT1 and HTR1A geno-
types in conjunction, these variables were forced into a multiple
model. Statistical signiﬁcance, odds ratio, and associated conﬁ-
dence intervals were estimated for each remaining parameter from
this multiple model. Interactions between gene variants were also
tested in this model.
RESULTS
The two sample cohorts for this study were combined and con-
sisted of a total of 367 patients (131 males, 236 females) with
a mean age of 33.3 years (SD 10.9 years). There was no signiﬁ-
cant difference in the age distribution of males and females [mean
male age 33.1 years (SD 11.0 years); mean female age 33.5 years
(SD 10.9 years)]. The range of the data was 18–63 years in both
males and females. Out of the full combined cohort, a valid diag-
nosis of whether or not the patient had BPD was recorded for 347
patients, with 50 (14.4%) having a positive diagnosis of BPD and
297 (85.6%) having no diagnosis of BPD. Table 1 gives a summary
1http://analysis2.bio-x.cn/myAnalysis.php
Table 1 |The frequency of age, gender and DAT1 and HTR1A
genotypes, with the prevalence of BPD.
Variable Frequency (%)
BPD No BPD Total1
Age [mean (SD)] 29.5 (8.5) 34.4 (11.2) 33.3 (10.9)
Gender
Male 16 (4.4%) 115 (31.3%) 131 (35.7%)
Female 34 (9.3%) 202 (55.0%) 236 (64.3%)
All 50 (13.6%) 317 (86.4%) 367 (100%)
Genotype
HTR1A
C,C 8 (2.9%) 64 (23.1%) 72 (26.1%)
C,G 13 (4.7%) 131 (47.5%) 144 (52.2%)
G,G 12 (4.3%) 48 (17.4%) 60 (21.7%)
All HTR1A 33 (12.0%) 243 (88.0%) 276 (100.0%)
DAT1
10,10 15 (4.7%) 178 (55.5%) 193 (60.1%)
9,10 21 (6.5%) 88 (27.4%) 109 (34.0%)
9,9 5 (1.6%) 14 (4.4%) 19 (5.9%)
All DAT1 41 (12.8%) 280 (87.2%) 321 (100%)
BPD, borderline personality disorder. 1Includes cases for which BPD status was
not recorded. Percentages may not sum to 100% due to rounding.
of the frequencies of patients for whom the HTR1A genotypes
were recorded, and for whom the DAT1 genotype was recorded
and validated from a previous study. The variants were in HWE
(HTR1A, p = 0.52; DAT1; p = 0.77).
The relative frequencies of BPD in patients with certain allele
combinations were compared. The incidence of BPD in patients
with the 9,9, variant (ﬁve out of 19; 26.3%); or the 9,10 variant
of the DAT1 gene (21 out of 106; 19.8%) was 2.36 times greater
than the incidence of BPD in patients with the 10,10 variant (15
out of 179; 8.4%). The incidence of BPD in patients with the
G,G variant of the HTR1A gene (12 out of 60; 20.0%) was 1.75
times the incidence of BPD in patients with the C,C variant (eight
out of 70; 11.4%) or the C,G variant of this gene (13 out of 136;
9.6%).P-values, odds ratios, and associated 95% conﬁdence inter-
vals (CIs) for all parameters considered in uncontrolled logistic
regression models are summarized in Table 2.
The Age parameter exhibited a substantive or statistically sig-
niﬁcant association with the outcome and were carried forward
for inclusion in a multiple logistic regression model, together with
all indicator variables modelling the DAT1 and HTR1A genotypes.
Gender was not found to exhibit a substantive or statistically sig-
niﬁcant association with the outcome and was not considered in
a multiple model. No interactions were found to be signiﬁcantly
associated with the outcome: following standard procedures, all
interactions were removed and the model re-cast as a main effects
model. The output from this model is summarized in Table 3.
When controlling for other factors and covariates, age and
HTR1A, DAT1 variants were signiﬁcantly associated with the inci-
dence of BPD (Table 2). ForHTR1A, a comparison of the reference
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Table 2 | Results from an uncontrolled logistic regression models (all
considered parameters) predicting BPD.
Variable OR 95% CI for OR p
Age 0.96 (0.93, 0.99) 0.004
Gender 1.13 (0.60, 2.14) 0.712
DAT1 genotypes
10,10 (reference)
9,10 2.20 (1.13, 4.27) 0.020
9,9 2.47 (0.84, 7.27) 0.101
HTR1A genotypes
C,C (reference)
C,G 0.58 (0.28, 1.22) 0.153
G,G 2.20 (1.01, 4.79) 0.046
Interactions
(9,10 × C,G) 3.08 (0.58, 16.4) 0.188
(9,10 × G,G) 1.32 (0.27, 6.58) 0.735
(9,9 × C,G) 1.53 (0.10, 24.4) 0.762
(9,9 × G,G) 0.68 (0.04, 11.7) 0.792
BPD, borderline personality disorder; OR, odds ratio; CI, conﬁdence interval.
category of the HTR1A gene with the other two categories (C,G
and G,G) appears to show non-signiﬁcance of the variant with
BPD. The odds of the BPD in patients with G,G genotypes [2.02;
95% CI: (1.10, 4.79)] are signiﬁcantly greater than the odds in
patients who have the C,G genotype (0.58; 95% CI 0.28, 1.22):
however, this comparison is not shown in Table 2 as C,G was not
selected as the reference category. Furthermore, the G,G geno-
type shows some degree of substantive signiﬁcance with respect to
the reference category of C,C (p = 0.171), while failing to reach
statistical signiﬁcance at the 5% level.
Higher incidences of BPD are found in younger patients, with
the odds of BPD incidence reducing by about 5% for each year
of age. Higher incidences of BPD are also found in patients with
Table 3 | Results from a multiple logistic main effects regression
model predicting BPD.
Variable Adjusted OR 95% CI for OR p
Age 0.95 (0.91, 0.99) 0.011
DAT1 genotypes
10,10 (reference)
9,10 3.27 (1.42, 7.48) 0.005
9,9 2.67 (0.63, 11.3) 0.183
HTR1A genotypes
C,C (reference)
C,G 0.72 (0.27, 1.92) 0.511
G,G 2.03 (0.74, 5.58) 0.171
BPD, borderline personality disorder; OR, odds ratio; CI, conﬁdence interval.
the 9,9 and 9,10 variants of the DAT1 gene than in patients with
the 10,10 variant. Similarly, higher incidences of BPD are found in
patients with the G,G variant of the HTR1A gene than in patients
with the C,G and C,C variants of this gene.
To explore the risk of BPD from both HTR1A and DAT1
genotypes, the effect associated with speciﬁc combinations of
these genotypes were considered. The effect of both the DAT1
and HTR1A variants results in a compounding of odds ratios
(Table 4). The highest odds of BPD occurred in patients homozy-
gous with the G,G allele of the HTR1A gene and either the 9,10
(OR, 6.64) or 9,9 (OR, 5.42) of the DAT1 gene. The lowest risk
category, which was below the baseline risk of 1 or reference cat-
egory (10,10; C,C), was 10,10; C,G. The risk ratio between the
highest (9,10; G,G) and lowest (10,10; C;G) risk categories was
9.22. Conversely the effect of the presence of a particular vari-
ant of the DAT1 gene may “cancel” the effect of another variant
of the HTR1A gene: for example the odds of BPD occurrence
in patients with the 9,10 variants of the DAT1 gene, and the
C,G variants of the HTR1A gene are within 18% of the odds
of BPD occurrence in a patient with the reference categories of
the 10,10 variant of the DAT1 gene and the G,G variant of the
HTR1A gene.
DISCUSSION
In a previous study we identiﬁed that BPD was signiﬁcantly asso-
ciated with the DAT1 9-repeat allele variant (Joyce et al., 2006). In
this study, the odds ratios associated with the DAT1 9-repeat allele
(either 9,9 or 9,10) are consistent with our previous study, which
was an analysis of a similar (but not identical) data set (Joyce et al.,
2006). In the current study, however, the effect of the 9-repeat
allele is considered as a controlling variable when assessing the
effect of the HTR1A rs6295 allele in BPD. By contrast, the analysis
of Joyce et al. (2006) focused on the DAT1 allele as the key experi-
mental variable and did not consider its effect in conjunction with
the HTR1A allele.
The current study conﬁrms that the HTR1A G allele increased
the risk of BPD when controlling for the presence of the DAT1
9,9 variant. Two previous studies failed to ﬁnd a positive link
Table 4 | Baseline risk of BPD (DAT1 10,10 and HTR1A C,C) = 1.00, with
frequencies of gene combinations.
Risk categories Frequency Adjusted OR (95% CI)
10,10; C,C 44 (16.3%) –
10,10; C,G 81 (30.0%) 0.72 (0.27, 1.92)
10,10; G,G 33 (12.2%) 2.03 (0.74, 5.58)
9,10; C,C 21 (7.8%) 3.27 (1.42, 7.48)
9,10; C,G 54 (20.0%) 2.35 (1.42, 3.88)
9,10; G,G 21 (7.8%) 6.62 (3.62, 12.12)
9,9; C,C 6 (2.2%) 2.67 (0.63, 11.27)
9,9; C,G 6 (2.2%) 1.92 (0.68, 5.44)
9,9; G,G 4 (1.5%) 5.40 (1.67, 17.4)
BPD, borderline personality disorder; OR, odds ratio. Risk ratio between highest
(9,10;G,G) and lowest (10,10;C,G) risk categories = 9.22.
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between theHTR1AGallele andBPD (Serretti et al., 2007; Ni et al.,
2009), and although our study did not reach statistical signiﬁcance,
individuals with theG,G genotype showed an increase risk of BPD.
The analysis also revealed a signiﬁcant increase in BPD when the
two risk alleles were present on both genes. The odds of BPD in
patients in highest risk categories were those with the G,G variant
of HTR1A and either 9,9 (OR, 5.42) or 9,10 (OR 6.64) genotypes
of DAT1. Moreover, the odds of BPD in patients with the highest
risk category (9,10; G,G) were about nine times greater than those
in the lowest risk category (10,10; C,G). The sub-group including
patients at highest risk had an incidence of BPD of 25.3% (18 out
of 71): nearly double the overall incidence rate in the full cohort.
Neither the number of 9-repeats of the DAT1 gene, nor the
number of instances of the G allele in the HTR1A gene, seems to
be additive effects. This suggests that a simplermodel, in which the
9,10 and 9,9 variants of the DAT1 gene are merged together, and
the C,G and C,C variants of the HTR1A gene are merged together,
may provide an adequate summary of the data.While both the 9,9
and 9,10 variants of the DAT1 allele were found to be associated
with BPD to a signiﬁcantly greater extent than the 10,10 variant in
an uncontrolled model, in a multiple model the incidence of BPD
associated with the 9,9 variant was not signiﬁcantly greater than
the incidence of BPD associated with the 10,10 variant. This may
be due to the relationships between gene variants.
One potential limitation of these ﬁndings is that the associ-
ation has been found in clinical samples of depressed patients.
In the community, the prevalence of BPD is about 1–2%, but in
out-patient samples it is often 10–15% (Hyman, 2002). Mood dis-
orders increase the risk of BPD. Any depression sample is thus an
“enriched” sample, and it is possible that our ﬁndings in two com-
bined depressed samples may not extend to the minority of BPD
patientswhodonot suffer fromdepression. Another consideration
is samples size and the possibility of false positives. However, with
367 patients, including 50 cases of BPD, the study was deemed
adequately powered to detect any signiﬁcant effects. Simulation
studies by Peduzzi et al. (1996) suggest that with the number of
positive cases, up to ﬁve variables may be considered in a mul-
tiple logistic regression model without compromising stability of
parameter estimates. The sample size and number of positive BPD
cases in our model is hence within acceptable limits.
Genetic factors contributing to BPD are thought to be only
modest (Torgersen, 2000) and that the environment may have a
signiﬁcant impact on the development of BPD. However, twin
studies of BPD have shown that 35–69% of the variance in
BPD is caused by genetics (meaning that respectively 65% to
31% of the variance in BPD is caused by other factors, such
as environment; Loranger et al., 1982; Torgersen, 2000; Zanarini
et al., 2004; Distel et al., 2008b). This suggests that BPD has at
least moderate genetic cause and is most likely an interaction
of genes and environment leading to BPD. From our obser-
vations it is apparent that genetic factors contributing to BPD
may be as a result of more than one risk variant, and con-
sequently the involvement of more than one neurotransmitter
system in traits underlying BPD. The complexity of BPD there-
fore cannot be delineated by single gene effects alone, which
may explain, in part, why previous studies investigating the
HTR1A G allele and BPD have been negative (Serretti et al.,
2007; Ni et al., 2009). However, Zetzsche et al. (2008) revealed
that BPD patients harboring the HTR1A G allele were signiﬁ-
cantly more likely to have a decrease in amygdala volume. The
amygdala is part of the limbic system and controls negative emo-
tion. Hyperactivation of the amygdala observed in BPD (Herpertz
et al., 2001; Guitart-Masip et al., 2009), may reﬂect the height-
ened response to emotionally relevant environmental stressors
in individuals with this disorder (Herpertz et al., 2001). Loss of
inhibitory regulation in the amygdala results in disinhibited fear
response, anger, and impulsive-aggressive behavior: core charac-
teristics of BPD (Phillips and LeDoux, 1992). Promoter studies
have shown that the minor G allele increases HTR1A activity
(Czesak et al., 2012), and as an autoreceptor could conceivably
reduce serotonergic function. Indeed, low levels of the serotonin
metabolite, 5-hydroxyindoleacetic acid, have been detected in the
cerebrospinal ﬂuid of BPD patients (Brown et al., 1982). Reduced
serotonergic function could conceivably inhibit the ability of this
neurotransmitter system to modulate or control impulsive and
aggressive behavior in BPD individuals.When combinedwith dys-
function in the dopaminergic system, potentially through DAT1,
this could increase the susceptibility to BPD. Therefore, to fully
understand the etiology of BPD, there is a clear need to interrogate
multiple genetic factors and/or neurotransmitter systems in more
depth.
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